Industry’s embrace of personalized medicine and rare diseases may leave major markets underserved, and FDA’s top new-drug official wants to see more development aimed at primary care markets – even if it means more “me-too” products.
For years, industry has been taking R&D smaller and smaller as it focuses on rare diseases and subsets of larger diseases in pursuit of precision medicine, as the ability to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?